JP2025505632A - 上昇したＨｂＡ１ｃを有する対象における体重減少の方法 - Google Patents

上昇したＨｂＡ１ｃを有する対象における体重減少の方法 Download PDF

Info

Publication number
JP2025505632A
JP2025505632A JP2024546294A JP2024546294A JP2025505632A JP 2025505632 A JP2025505632 A JP 2025505632A JP 2024546294 A JP2024546294 A JP 2024546294A JP 2024546294 A JP2024546294 A JP 2024546294A JP 2025505632 A JP2025505632 A JP 2025505632A
Authority
JP
Japan
Prior art keywords
subject
reduction
effective amount
therapeutically effective
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505632A5 (https=
JPWO2023150759A5 (https=
Inventor
シャハリヤール カーン，
ダイアン ジョカスキー，
フランシスコ ポルテル，
Original Assignee
リーバス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リーバス ファーマシューティカルズ， インコーポレイテッド filed Critical リーバス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2025505632A publication Critical patent/JP2025505632A/ja
Publication of JP2025505632A5 publication Critical patent/JP2025505632A5/ja
Publication of JPWO2023150759A5 publication Critical patent/JPWO2023150759A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024546294A 2022-02-07 2023-02-06 上昇したＨｂＡ１ｃを有する対象における体重減少の方法 Pending JP2025505632A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263307470P 2022-02-07 2022-02-07
US63/307,470 2022-02-07
US202263382426P 2022-11-04 2022-11-04
US63/382,426 2022-11-04
PCT/US2023/062065 WO2023150759A1 (en) 2022-02-07 2023-02-06 Methods of weight loss in a subject with elevated hba1c

Publications (3)

Publication Number Publication Date
JP2025505632A true JP2025505632A (ja) 2025-02-28
JP2025505632A5 JP2025505632A5 (https=) 2026-02-16
JPWO2023150759A5 JPWO2023150759A5 (https=) 2026-02-16

Family

ID=85569618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546294A Pending JP2025505632A (ja) 2022-02-07 2023-02-06 上昇したＨｂＡ１ｃを有する対象における体重減少の方法

Country Status (9)

Country Link
US (1) US20250134865A1 (https=)
EP (1) EP4475842A1 (https=)
JP (1) JP2025505632A (https=)
KR (1) KR20240146053A (https=)
AU (1) AU2023214495A1 (https=)
CA (1) CA3243643A1 (https=)
IL (1) IL314682A (https=)
MX (1) MX2024009644A (https=)
WO (1) WO2023150759A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo
WO2022246039A1 (en) * 2021-05-20 2022-11-24 Rivus Pharmaceuticals, Inc. Methods of treating mitochondria-related disorders

Also Published As

Publication number Publication date
MX2024009644A (es) 2024-08-14
EP4475842A1 (en) 2024-12-18
WO2023150759A1 (en) 2023-08-10
IL314682A (en) 2024-10-01
AU2023214495A1 (en) 2024-08-15
US20250134865A1 (en) 2025-05-01
KR20240146053A (ko) 2024-10-07
CA3243643A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
US11400072B2 (en) Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2017513836A (ja) Ｎａｆｌｄおよびｎａｓｈの治療
CN113301889A (zh) Nafld和nash的联合治疗
CN117677395A (zh) 长效glp1/胰高血糖素受体激动剂的剂量方案
TW202114671A (zh) 包含fxr促效劑之治療
US20250177353A1 (en) Methods of treating mitochondria-related disorders
US20250134864A1 (en) Methods of weight loss and preserving skeletal muscle mass
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
JP2025505632A (ja) 上昇したＨｂＡ１ｃを有する対象における体重減少の方法
CN118900692A (zh) HbA1c升高的受试者的体重减轻方法
CN118922187A (zh) 体重减轻和保持骨骼肌量的方法
TW202500575A (zh) 具有或不具有體重相關合併症之過重或肥胖成人之治療
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
CN117881399A (zh) 治疗粒线体相关病症的方法
WO2026037397A1 (zh) Glp-1类似物的医药用途
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
TW202033199A (zh) 化合物ａ與化合物ｂ聯合在製備治療痛風或高尿酸血症的藥物中的用途
EA042686B1 (ru) Способ лечения неалкогольного стеатогепатита

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260205